Inj amivantamab 5mg hyaluron
Products billed under this code include Rybrevant Faspro.
Payment limit per 5 MG, by effective quarter, 3Q26 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under J9062
From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Rybrevant Faspro | Janssen Biotech, Inc. | 57894-0510-01 | 320 | $12,957.44 |
| Rybrevant Faspro | Janssen Biotech, Inc. | 57894-0514-01 | 448 | $18,140.416 |
| Rybrevant Faspro | Janssen Biotech, Inc. | 57894-0515-01 | 480 | $19,436.16 |
| Rybrevant Faspro | Janssen Biotech, Inc. | 57894-0522-01 | 704 | $28,506.368 |
Every quarter
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $40.492 | −$0.251 | 5 MG | Inj amivantamab 5mg hyaluron | v1, posted September 17, 2026 |
| 3Q26 | $40.743 | – | 5 MG | Inj amivantamab 5mg hyaluron | v1, posted September 15, 2026 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.
CMS source files
- 4Q26: 2026-09-17_october-2026-medicare-part-b-payment-limit-files-final.zipposted September 17, 2026
- 4Q26: 2026-09-17_october-2026-ndc-hcpcs-crosswalk-final.zipposted September 17, 2026
- 3Q26: 2026-09-15_july-2026-medicare-part-b-payment-limit-files.zipposted September 15, 2026